latest update:
[TrialBase DB]

trial summary · NCT07780838

Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma

A Phase IIa Clinical Trial of First-Line Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for Advanced Biliary Tract Cancers With FGFR2 Alterations

Trial record from the TrialBase DB dataset, status RECRUITING, condition Locally Advanced Ampulla of Vater Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07780838phase PHASE2enrollment 29start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase II trial tests how well giving gemcitabine, cisplatin and durvalumab alternating with pemigatinib for the treatment of biliary tract cancer with FGFR2 alterations that cannot be removed by surgery (unresectable), that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pemigatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them. Giving gemcitabine, cisplatin and durvalumab alternating with pemigatinib may work well for the treatment of unresectable, locally advanced or metastatic biliary tract cancer with FGFR2 alterations.

Source record: https://clinicaltrials.gov/study/NCT07780838

Facts

registry idNCT07780838
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionLocally Advanced Ampulla of Vater Carcinoma
sponsorOhio State University Comprehensive Cancer Center
sponsor classOTHER
enrollment29
start date2026-11-01
primary completion2027-12-31
completion2027-12-31
results postednot reported

Conditions

  • Locally Advanced Ampulla of Vater Carcinoma
  • Locally Advanced Biliary Tract Carcinoma
  • Locally Advanced Extrahepatic Cholangiocarcinoma
  • Locally Advanced Gallbladder Carcinoma
  • Locally Advanced Intrahepatic Cholangiocarcinoma
  • Metastatic Ampulla of Vater Carcinoma
  • Metastatic Biliary Tract Carcinoma
  • Metastatic Extrahepatic Cholangiocarcinoma
  • Metastatic Gallbladder Carcinoma
  • Metastatic Intrahepatic Cholangiocarcinoma
  • Stage III Ampulla of Vater Cancer AJCC v8
  • Stage III Distal Bile Duct Cancer AJCC v8

11 more in the dataset.

Interventions

  • Biospecimen Collection
  • Cisplatin
  • Computed Tomography
  • Durvalumab
  • Gemcitabine
  • Magnetic Resonance Imaging
  • Pemigatinib
  • Survey Administration

Countries

  • United States

Intervention types: BIOLOGICAL, DRUG, OTHER, PROCEDURE

Work with this record